Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death‐1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105‐204)
- 27 February 2024
- Vol. 130 (12) , 2180-2190
Abstract
Background: Penpulimab, a new‐generation antiprogrammed cell death‐1 immunoglobulin G1 monoclonal antibody, was engineered to optimize receptor occupancy and eliminate fragment crystallizable γ‐mediated effector function. In this multicenter, phase 1b/2, multicohort study, the objective was to investigate the efficacy, safety, and immunogenicity of penpulimab in advanced solid tumors.Methods: Patients who had unresectable, advanced solid tumors were enrolled from six centers and received 200 mg penpulimab on day 1 every 2 weeks for up to 24 months. The primary end point was the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors, version criteria 1.1.Results: Between September 2, 2019, and January 1, 2020, 65 patients were enrolled and received penpulimab. At the time of data cutoff (May 11, 2022), the median follow‐up was 12.6 months (range, 1.1–28.6 months). The ORR was 12.3 (95% confidence interval [CI], 5.5%–22.8%), with three (4.6%) complete responses and five (7.7%) partial responses. Twelve patients (18.5%) achieved stable disease, resulting in a disease control rate of 30.8% (95% CI, 19.9%–43.4%). The median duration of response was not reached (95% CI, 6.70 months to not estimable). In all cohorts, the median progression‐free survival was 1.74 months (95% CI, 1.41–2.69 months), and the median overall survival was 16.59 months (95% CI, 7.82–22.18 months). Grade 3 or greater treatment‐related adverse events and immune‐related adverse events occurred in 9.2% and 27.7% of patients, respectively. Positive antidrug antibody responses to penpulimab were observed in one patient (1.8%).Conclusions: Penpulimab showed promising antitumor activity with an acceptable safety profile, offering a potential new treatment approach for solid tumors. These findings supported the evaluation of penpulimab's durable activity and safety, as monotherapy or in combination therapy, in specific malignancies.Keywords
This publication has 22 references indexed in Scilit:
- 59MO Final analysis of AK105-302: A randomized, double-blind, placebo-controlled, phase III trial of penpulimab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLCImmuno-Oncology and Technology, 2022
- 2O Penpulimab, an IgG1 anti-PD-1 antibody with Fc-engineering to eliminate effector functions and with unique epitope and binding propertiesAnnals of Oncology, 2021
- Using the Common Terminology Criteria for Adverse Events (CTCAE – Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer TherapiesActas Dermo-Sifiliograficas, 2021
- Clinical Challenges of Immune Checkpoint InhibitorsCancer Cell, 2020
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challengesNature Reviews Clinical Oncology, 2018
- Cancer immunotherapy and the value of cureNature Reviews Clinical Oncology, 2018
- Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid TumorsThe Journal of Clinical Pharmacology, 2016
- Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG FrameworkCancer Cell, 2015
- FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 AxisCancer Cell, 2015
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009